Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Outcomes
100%
Risk Stratification
100%
Acute Myocardial Infarction
100%
Secondary Prevention
100%
Preventive Treatment
57%
Clinical High Risk
42%
Risk Level
28%
Low Dose Rate
14%
Hazard Ratio
14%
High Risk
14%
Myocardial Infarction
14%
Beta-blockers
14%
France
14%
Angiotensin-converting Enzyme Inhibitor (ACEi)
14%
Low Risk
14%
Intermediate Risk
14%
Major Adverse Cardiovascular Events
14%
Recommended Treatment
14%
Evidence-based Treatment
14%
Long-term Clinical Outcome
14%
Medication Regimen
14%
Patient Risk
14%
Cardiac Intensive Care Unit
14%
ST-elevation Myocardial Infarction (STEMI)
14%
P2Y12 Inhibitors
14%
French Registry
14%
Dual Antiplatelet Therapy
14%
95% Confidence Interval
14%
Thrombolysis in Myocardial Infarction Score
14%
Acute Myocardial Infarction Patients
14%
Medicine and Dentistry
Myocardial Infarction
100%
Risk Stratification
100%
Acute Heart Infarction
100%
Secondary Prevention
100%
Prevalence
14%
Drug Megadose
14%
Cardiovascular Disease
14%
ST Elevation
14%
Hazard Ratio
14%
Statin
14%
Apoplexy
14%
Blood Clot Lysis
14%
ACE Inhibitor
14%
Antiplatelet
14%
Angiotensin Receptor Antagonist
14%
Beta Adrenergic Receptor Blocking Agent
14%
Coronary Care Unit
14%
Non ST Segment Elevation Myocardial Infarction
14%
Nursing and Health Professions
Acute Heart Infarction
100%
Clinical Outcome
100%
Secondary Prevention
100%
Practice Guideline
14%
Prevalence
14%
Confidence Interval
14%
Hazard Ratio
14%
Cardiovascular Disease
14%
Heart Infarction
14%
Dipeptidyl Carboxypeptidase Inhibitor
14%
Coronary Care Unit
14%
Drug Megadose
14%
Cerebrovascular Accident
14%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
14%
Beta Adrenergic Receptor Blocking Agent
14%
Non ST Segment Elevation Myocardial Infarction
14%
Dual Antiplatelet Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Heart Infarction
100%
Prevalence
25%
Heart Infarction
25%
Dipeptidyl Carboxypeptidase Inhibitor
25%
Antiplatelet
25%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
25%
Beta Adrenergic Receptor Blocking Agent
25%
Angiotensin Receptor Antagonist
25%
Cerebrovascular Accident
25%
Cardiovascular Disease
25%
Non ST Segment Elevation Myocardial Infarction
25%
Heart Reinfarction
25%